MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type...

Area of Science:

• Neuro-oncology
• Molecular Diagnostics
• Cancer Biology

Background:

• O6-methylguanine DNA methyltransferase (MGMT) promoter methylation is a key predictive marker in glioblastoma (GBM).
• The relationship between MGMT status and pretreatment tumor biology in IDH-wildtype GBM remains underexplored.
• Understanding this relationship could refine prognostic assessments and treatment strategies.

Purpose of the Study:

• To investigate the association between MGMT promoter methylation status and various pretreatment phenotypical tumor biology features in IDH-wildtype GBM.
• To determine if MGMT status can serve as a surrogate marker for histopathological and radiological characteristics.
• To assess the impact of MGMT status on overall survival in this patient cohort.

Main Methods:

• Analysis of 85 isocitrate dehydrogenase (IDH) wild-type GBM samples.
• MGMT promoter methylation assessed by methylation-specific PCR.
• Correlation analysis with 22 histopathological features, immunohistochemical markers (proliferative index, microvessel density), and conventional MRI characteristics.
• Evaluation of preoperative tumor growth speed and overall survival.

Main Results:

• No significant associations were found between MGMT methylation status and any of the investigated histopathological or radiological features.
• Methylated MGMT status emerged as a significant independent predictor of improved overall survival.
• Conventional MRI features could not reliably predict MGMT status noninvasively.

Conclusions:

• MGMT promoter methylation status is not associated with pretreatment phenotypical tumor biology in IDH-wildtype GBM.
• The survival advantage observed in MGMT-methylated GBMs does not appear to stem from inherently less aggressive tumor biology.
• Current conventional MRI techniques are insufficient for noninvasive prediction of MGMT status in GBM.